Related Articles for PubMed (Select 12848894)

Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment.

Pandey M, Chandramohan K.

World J Surg Oncol. 2003 Jul 1;1(1):9. No abstract available.

PMID: 12848894 [PubMed - as supplied by publisher]

Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.

Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE.

J Natl Cancer Inst. 1997 Oct 15;89(20):1505-15.

PMID: 9337347 [PubMed - indexed for MEDLINE]

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID: 15075904 [PubMed - indexed for MEDLINE]

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.

Calvo E, Rowinsky EK.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S35-42. Review.

PMID: 15638956 [PubMed - indexed for MEDLINE]

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

Stadick H, Stockmeyer B, Kühn R, Schrott KM, Kalden JR, Glennie MJ, van de Winkel JG, Gramatzki M, Valerius T, Elsässer D.

J Urol. 2002 Feb;167(2 Pt 1):707-12.

PMID: 11792958 [PubMed - indexed for MEDLINE]

Novel combinations based on epidermal growth factor receptor inhibition.

Adjei AA.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4446s-4450s. Review.

PMID: 16857826 [PubMed - indexed for MEDLINE]

Role of an anti-epidermal growth factor receptor in treating cancer.

Waksal HW.

Cancer Metastasis Rev. 1999;18(4):427-36. Review.

PMID: 10855786 [PubMed - indexed for MEDLINE]

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

Ritter CA, Arteaga CL.

Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11. Review.

PMID: 12644979 [PubMed - indexed for MEDLINE]

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama AB, Hynes NE, Lane HA.

Cancer Res. 2002 Jun 1;62(11):3151-8.

PMID: 12036928 [PubMed - indexed for MEDLINE]

10:

Epidermal growth factor receptor as a therapeutic target in lung cancer.

Schiller JH.

Semin Respir Crit Care Med. 2004;25 Suppl 1:11-6.

PMID: 16088516 [PubMed]

11:

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

Raymond E, Faivre S, Armand JP.

Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. Review.

PMID: 11129168 [PubMed - indexed for MEDLINE]

12:

[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors]

Tamura T.

Nippon Geka Gakkai Zasshi. 2002 Feb;103(2):233-6. Review. Japanese.

PMID: 11904986 [PubMed - indexed for MEDLINE]

13:

Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.

Scartozzi M, Pierantoni C, Berardi R, Antognoli S, Bearzi I, Cascinu S.

Anal Quant Cytol Histol. 2006 Apr;28(2):61-8. Review.

PMID: 16637508 [PubMed - indexed for MEDLINE]

14:

Epidermal growth factor receptor as a major anticancer drug target.

Caponigro F, Milano A, Ottaiano A, Iaffaioli RV.

Expert Opin Ther Targets. 2006 Dec;10(6):877-88. Review.

PMID: 17105374 [PubMed - indexed for MEDLINE]

15:

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.

Mol Cancer Ther. 2005 Jan;4(1):101-12.

PMID: 15657358 [PubMed - indexed for MEDLINE]

16:

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.

Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, Morelli MP, Cascone T, Tortora G.

Ann Oncol. 2006 Jun;17 Suppl 7:vii109-14. Review.

PMID: 16760272 [PubMed - indexed for MEDLINE]

17:

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K.

Anticancer Drugs. 2006 Aug;17(7):783-95.

PMID: 16926628 [PubMed - indexed for MEDLINE]

18:

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.

Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.

J Nucl Med. 2003 Sep;44(9):1469-78.

PMID: 12960194 [PubMed - indexed for MEDLINE]

19:

Epidermal growth factor receptor inhibitors: a novel anticancer therapy.

Donegan SE, Naples KM.

Cancer Pract. 2002 Jan-Feb;10(1):53-6. No abstract available.

PMID: 11866711 [PubMed - indexed for MEDLINE]

20:

Targeted therapy for colorectal cancer.

Hwang J, Marshall JL.

Curr Opin Investig Drugs. 2006 Dec;7(12):1062-6. Review.

PMID: 17209523 [PubMed - indexed for MEDLINE]

Recent Activity